We have evaluated in normal subjects the effect of H1 antagonists meclastine, dexchlorpheniramine and promethazine) and of the H2 antagonist cimetide on basal and stimulated IRI and IRG release in 78 healthy subjects. Both cimetidine and H1 antagonists, acutely administered, reduce fasting IRI levels, placebo being ineffective. Results obtained with single H1 antagonists are pooled, being generally superimposable. IRG release is unaffected by any treatment. IRI response to arginine is enhanced by H1 antagonists, while cimetidine is ineffective. Cimetidine enhances the A-cell IRG response to arginine and reduces its response to hypoglycemia. A-cell IRG and total IRG response to arginine or to hypoglycemia are not affected by H1 antagonists or by placebo. The IRI response to i.v. glucose and the blood-glucose pattern after arginine, i.v. glucose or i.v. insulin, are not affected by cimetidine or by H1 antagonists.
|Number of pages||2|
|Journal||Hormone and Metabolic Research|
|Publication status||Published - 1982|
ASJC Scopus subject areas